Sernova Corp Engages Ray Matthews & Associates

Sernova Corp. (TSX VENTURE:SVA), is pleased to announce that it is has engaged
Ray Matthews & Associates Inc. ('RM&A') to provide capital markets and advisory
services, including investor relations activities.


"Ray Matthews and his team have a proven track record in providing strategic
counsel for emerging growth companies," stated Dr. Philip Toleikis, President
and CEO of Sernova Corp. "Ray Matthews and Associates joins Sernova at an
exciting time with the Company focused on partnering and monetizing our
pipeline. Our Company will benefit from RM&A's broad range of experience in
strategic planning, corporate development, investor relations and operational
consultation," Dr. Toleikis added. 


"Sernova has a pipeline and IP portfolio which has the potential to achieve
substantial shareholder value. I am excited to be able to add value and help
attract additional talent and networks to help Sernova achieve its full
potential," commented Ray Matthews. 


Among other things, RM&A will facilitate communications between the Company and
its shareholders and prospective investors and implement programs to raise
awareness of the Company's business among prospective investors and the
investment community. For more information on RM&A Inc., please visit
www.raymatthews.ca. 


Under the terms of the Company's agreement with RM&A, the Company will pay to
RM&A a cash fee of $4,750 per month for six months and grant to RM&A a total of
160,000 incentive stock options, each option being exercisable, once vested,
into one common share of the Company at a purchase price of $0.15 per share. The
options shall vest in four equal quarterly installments, with the first 45,000
options vesting on December 5, 2013, and will be governed by the Company's
option plan and the policies of the TSX Venture Exchange.


About Sernova 

Sernova Corp is a clinical stage company developing medical technologies for the
treatment of chronic debilitating metabolic diseases such as diabetes, blood
disorders including hemophilia and other diseases to replace proteins or
hormones in short supply within the body. Sernova is developing the Cell
Pouch(TM), an implantable medical device which when placed under the skin forms
an environment rich in tissue matrix and microvessels, ideal for placing
therapeutic cells which then release proteins and/or hormones as required. The
therapeutic cells are protected from immune attack by Sernova's proprietary
technology Sertolin(TM) which provides an immune-protected environment for the
therapeutic cells.


About the Cell Pouch(TM) 

The Cell Pouch(TM) is a proprietary scalable medical device which has been
contract manufactured (ISO13485). It is placed under the skin, and forms an
ideal environment rich in microvessels and tissue matrix for the placement and
function of therapeutic cells. The Cell Pouch(TM) is currently being evaluated
in clinical trials at the University of Alberta with Dr. James Shapiro as
principal investigator in patients with Type 1 diabetes receiving an islet
transplant.


About Sertoli Cells 

Sertoli cells when co-localized with donor therapeutic cells release protective
factors that can provide a non-toxic, immune-protected environment that may
reduce or eliminate the need for daily anti-rejection drugs that currently must
be used by patients with transplanted tissues and organs. Sernova is currently
conducting studies to optimize sertoli cells and islets within the Cell
Pouch(TM) through a NRC-IRAP contribution agreement provided by the Government
of Canada. 


Forward Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Philip Toleikis, Ph.D., President and CEO
(604) 961-2939
info@sernova.com
www.sernova.com


Ray Matthews & Associates Inc.
Suite 601-128 West Cordova Street
Vancouver, BC V6B 0E6
www.raymatthews.ca
604.818.7778


Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
tony.russo@russopartnersllc.com
Sernova (TSXV:SVA)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024